Glaukos (GKOS) Competitors

Glaukos (NYSE:GKOS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Which has stronger earnings & valuation, GKOS or ZBH?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$314.71M	24.78	-$134.66M	-$3.02	-46.83
Zimmer Biomet	$7.39B	2.94	$1.02B	$5.26	20.78

Does the MarketBeat Community believe in GKOS or ZBH?

Zimmer Biomet received 461 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 67.24% of users gave Zimmer Biomet an outperform vote while only 64.51% of users gave Glaukos an outperform vote.

Company	Underperform	Outperform
Glaukos	Outperform Votes 438 64.51%	Underperform Votes 241 35.49%
Zimmer Biomet	Outperform Votes 899 67.24%	Underperform Votes 438 32.76%

Which has more risk and volatility, GKOS or ZBH?

Glaukos has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of GKOS or ZBH?

99.0% of Glaukos shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 6.4% of Glaukos shares are held by insiders. Comparatively, 0.7% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media favor GKOS or ZBH?

In the previous week, Zimmer Biomet had 10 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for Zimmer Biomet and 6 mentions for Glaukos. Glaukos' average media sentiment score of 1.09 beat Zimmer Biomet's score of 1.05 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	11 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate GKOS or ZBH?

Glaukos presently has a consensus target price of $134.55, suggesting a potential downside of 4.87%. Zimmer Biomet has a consensus target price of $123.22, suggesting a potential upside of 12.73%. Given Zimmer Biomet's higher possible upside, analysts clearly believe Zimmer Biomet is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Zimmer Biomet	2 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.20

Is GKOS or ZBH more profitable?

Zimmer Biomet has a net margin of 14.27% compared to Glaukos' net margin of -42.43%. Zimmer Biomet's return on equity of 12.95% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-42.43%	-18.99%	-11.47%
Zimmer Biomet	14.27%	12.95%	7.55%

Summary

Zimmer Biomet beats Glaukos on 11 of the 17 factors compared between the two stocks.